TP53 and Burkitt lymphoma: Consistent with the finding that the TP53 tumour suppressor pathway is frequently abrogated in human BL,26 there was no difference in survival of the EBV-loss and EBV-positive clones following treatment with the DNA damage inducers, etoposide and cisplatin (Supplementary Figure 3c and data not shown).